Side-by-side · Research reference
IGF-DESvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED8/60 cited
BFDA-ApprovedFlagship15/53 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
IGF-DES
Semaglutide
Primary target
IGF-1 receptor (IGF1R)Shields 2007
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Unknown — no human endocrine feedback data
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
IGF-DES
Semaglutide
Research dose range
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
—
Route
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
—
Frequency
Variable — daily to multiple times daily in research
Once weekly, same day each week
Evidence basis
Animal models + in vitro only
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Human data
None — no clinical trials
—
Half-life
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
03Metabolic / Fat Loss Evidence
Parameter
IGF-DES
Semaglutide
Primary mechanism
Indirect via muscle hypertrophy → metabolic rate elevation
—
Direct lipolysis
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
—
Prostate model
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
—
04Side Effects & Safety
Parameter
IGF-DES
Semaglutide
Hypoglycemia risk
Theoretical — IGF-1 axis enhances glucose uptake
—
Mitogenic risk
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
—
Injection site reaction
Expected — erythema, irritation, local swelling
Mild erythema, pruritus
Edema / Fluid retention
Possible via sodium retention (IGF-1 axis effect)
—
Human safety data
Absent — no human trials, all effects theoretical or extrapolated
—
Unknown long-term effects
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
IGF-DES
Semaglutide
1. Research context only
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Reconstitution (if lyophilized)
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Injection site
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Timing
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle gauge
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
6. Monitoring
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
—
06Stack Synergy
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)